Enterprise Value

0.00

Cash

123.6M

Avg Qtr Burn

N/A

Short % of Float

8.22%

Insider Ownership

28.01%

Institutional Own.

5.83%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TAVO™-EP + OPDIVO® (nivolumab) Details
Melanoma, Prostate cancer, Cancer

Phase 2

Data readout

TAVO™-EP + pembrolizumab Details
Melanoma, Rhabdomyosarcoma, Thermal burns, Non-small cell lung carcinoma, Cancer

Phase 2

Update

CORVax12 (TAVO + SARS-CoV-2 spike glycoprotein) Details
COVID-19, Hepatitis B vaccine, Hepatitis B

Failed

Discontinued

TAVO™-EP + epacadostat + pembrolizumab Details
Cancer, Head and neck cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

TAVO™-EP + pembrolizumab Details
Breast cancer, Triple-negative breast cancer

Failed

Discontinued